Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07494448CT.gov Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07648914CT.gov A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) | — | Not Yet Recruiting | — | — | — |
NCT07417241CT.gov SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | — | Not Yet Recruiting | — | — | — |
NCT07461454CT.gov YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT07222215CT.gov PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | — | Recruiting | — | — | — |
NCT07366840CT.gov RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure | — | Not Yet Recruiting | — | — | — |
NCT07318805CT.gov A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07007559CT.gov ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT07112053CT.gov A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07071337CT.gov A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | — | Recruiting | — | — | — |
Show 149 more trialsShow fewer
NCT07019337CT.gov Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07021261CT.gov Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | — | Not Yet Recruiting | — | — | — |
NCT06992336CT.gov Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06568692CT.gov A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06102824CT.gov Organoid-based Functional Precision Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06247995CT.gov A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06018337CT.gov A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | — | Active Not Recruiting | — | — | — |
NCT06268652CT.gov Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | — | Recruiting | — | — | — |
NCT06217185CT.gov The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | — | Recruiting | — | — | — |
NCT06156761CT.gov Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06112379CT.gov A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06081959CT.gov Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT05840211CT.gov Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | — | Active Not Recruiting | — | — | — |
NCT05564377CT.gov Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | — | Recruiting | — | — | — |
NCT04789096CT.gov Tucatinib Together With Pembrolizumab and Trastuzumab | — | Terminated | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT05629585CT.gov A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | — | Active Not Recruiting | — | — | — |
NCT05411380CT.gov Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | — | Unknown | — | — | — |
NCT05374512CT.gov A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | — | Active Not Recruiting | — | — | — |
NCT05227131CT.gov Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05163223CT.gov Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT05104866CT.gov A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | — | Active Not Recruiting | — | — | — |
NCT05063786CT.gov Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | — | Active Not Recruiting | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04721977CT.gov A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | — | Active Not Recruiting | — | — | — |
NCT04803539CT.gov A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | — | Recruiting | — | — | — |
NCT04556773CT.gov A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04780347CT.gov Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04681911CT.gov Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04494425CT.gov Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04274933CT.gov A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | — | Terminated | — | — | — |
NCT04355858CT.gov Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
NCT04158258CT.gov A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | — | Active Not Recruiting | — | — | — |
NCT04095390CT.gov A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | — | Unknown | — | — | — |
NCT03818685CT.gov Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | — | Unknown | — | — | — |
NCT03901339CT.gov Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03923166CT.gov Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03853707CT.gov Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT03501979CT.gov Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | — | Terminated | — | — | — |
NCT03858972CT.gov Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | — | Terminated | — | — | — |
NCT03473639CT.gov A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | — | Completed | — | — | — |
NCT04258163CT.gov Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | — | Completed | — | — | — |
NCT03734029CT.gov Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | — | Active Not Recruiting | — | — | — |
NCT03523585CT.gov DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | — | Completed | — | — | — |
NCT05833919CT.gov Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | — | Unknown | — | — | — |
NCT03424005CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT03383679CT.gov Study on Androgen Receptor and Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03326674CT.gov Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC | — | Terminated | — | — | — |
NCT03377387CT.gov Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02574455CT.gov Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | — | Completed | — | — | — |
NCT03322215CT.gov HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | — | Terminated | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT03084939CT.gov Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02955940CT.gov An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | — | Active Not Recruiting | — | — | — |
NCT02592746CT.gov A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | — | Unknown | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02338245CT.gov Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | — | Completed | — | — | — |
NCT02129556CT.gov Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT02934828CT.gov Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer | — | Unknown | — | — | — |
NCT02253459CT.gov Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02248571CT.gov Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | — | Completed | — | — | — |
NCT02213744CT.gov MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT02000882CT.gov STAR Cape+BKM120 MBC With Brain Met | — | Completed | — | — | — |
NCT02120417CT.gov A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | — | Terminated | — | — | — |
NCT02028507CT.gov Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | — | Completed | — | — | — |
NCT01349088CT.gov Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01875367CT.gov Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | — | Completed | — | — | — |
NCT01953003CT.gov Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT01939054CT.gov Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients | — | Unknown | — | — | — |
NCT01843725CT.gov Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers | — | Completed | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT02210364CT.gov Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | — | Completed | — | — | — |
NCT01887288CT.gov Capecitabine With Digoxin for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01803282CT.gov Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01783444CT.gov A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | — | Completed | — | — | — |
NCT01702558CT.gov A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) | — | Terminated | — | — | — |
NCT01937507CT.gov Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer | — | Terminated | — | — | — |
NCT01640665CT.gov Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | — | Completed | — | — | — |
NCT01609127CT.gov Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01494662CT.gov HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | — | Completed | — | — | — |
NCT01655992CT.gov A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) | — | Terminated | — | — | — |
NCT01528826CT.gov Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial | — | Unknown | — | — | — |
NCT04175171CT.gov Clinical Trial of Comparative Study of GB221 Pharmacokinetics | — | Completed | — | — | — |
NCT01300962CT.gov Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01439282CT.gov Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | — | Completed | — | — | — |
NCT01326481CT.gov Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01351597CT.gov A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01231802CT.gov Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01234402CT.gov Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients | — | Completed | — | — | — |
NCT01234337CT.gov Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01158274CT.gov RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT01132664CT.gov Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT01387295CT.gov Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease | — | Completed | — | — | — |
NCT01387373CT.gov Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer | — | Completed | — | — | — |
NCT01323530CT.gov A Confirmation Study of Eribulin in Combination With Capecitabine | — | Completed | — | — | — |
NCT00959946CT.gov Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01095003CT.gov Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | — | Completed | — | — | — |
NCT00967031CT.gov Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases | — | Completed | — | — | — |
NCT00777101CT.gov Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00829166CT.gov A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00741260CT.gov Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | — | Completed | — | — | — |
NCT00795678CT.gov Chemotherapeutic Agents in Brain/Breast | — | Completed | — | — | — |
NCT00684983CT.gov Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | — | Completed | — | — | — |
NCT00632489CT.gov LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | — | Completed | — | — | — |
NCT00568022CT.gov A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00479856CT.gov Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | — | Terminated | — | — | — |
NCT00473005CT.gov Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast | — | Terminated | — | — | — |
NCT00496366CT.gov Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer | — | Terminated | — | — | — |
NCT00508274CT.gov Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | — | Terminated | — | — | — |
NCT00493636CT.gov 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy | — | Completed | — | — | — |
NCT00452673CT.gov Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00477464CT.gov Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00437073CT.gov Brain Metastases In ErbB2-Positive Breast Cancer | — | Terminated | — | — | — |
NCT00450515CT.gov Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00437294CT.gov Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | — | Terminated | — | — | — |
NCT00337103CT.gov E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | — | Completed | — | — | — |
NCT00327743CT.gov Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00397761CT.gov Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | — | Withdrawn | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT00265733CT.gov Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00266799CT.gov The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | — | Completed | — | — | — |
NCT00227656CT.gov Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer | — | Terminated | — | — | — |
NCT00194792CT.gov Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | — | Terminated | — | — | — |
NCT00204776CT.gov XELOX for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00087152CT.gov S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00077363CT.gov Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00665457CT.gov Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | — | Terminated | — | — | — |
NCT00082095CT.gov To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older | — | Terminated | — | — | — |
NCT00081796CT.gov Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00078572CT.gov Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00082433CT.gov Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00068588CT.gov GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00080301CT.gov Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00070252CT.gov Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00159458CT.gov Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00049244CT.gov BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00153907CT.gov Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00193102CT.gov Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Beijing Biostar Pharmaceuticals Co., Ltd. | Approved | BB · 70 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Cyclophosphamide | Fudan University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →